JP2016135771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016135771A5 JP2016135771A5 JP2016001939A JP2016001939A JP2016135771A5 JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5 JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016001939 A JP2016001939 A JP 2016001939A JP 2016135771 A5 JP2016135771 A5 JP 2016135771A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functional part
- antibody according
- sdr
- epidermidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 3
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 241000192125 Firmicutes Species 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 241001147736 Staphylococcus capitis Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241001147695 Staphylococcus caprae Species 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22587809P | 2009-07-15 | 2009-07-15 | |
| US61/225,878 | 2009-07-15 | ||
| EP09165558.9 | 2009-07-15 | ||
| EP09165558 | 2009-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Division JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Division JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016135771A JP2016135771A (ja) | 2016-07-28 |
| JP2016135771A5 true JP2016135771A5 (enExample) | 2016-12-22 |
Family
ID=41467048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
| JP2016001939A Pending JP2016135771A (ja) | 2009-07-15 | 2016-01-07 | グラム陽性菌特異的結合化合物 |
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520555A Expired - Fee Related JP6192294B2 (ja) | 2009-07-15 | 2010-07-15 | グラム陽性菌特異的結合化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072444A Pending JP2018134089A (ja) | 2009-07-15 | 2018-04-04 | グラム陽性菌特異的結合化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US20110020323A1 (enExample) |
| EP (1) | EP2454284B1 (enExample) |
| JP (3) | JP6192294B2 (enExample) |
| KR (1) | KR101832201B1 (enExample) |
| CN (2) | CN102666583B (enExample) |
| AR (1) | AR077756A1 (enExample) |
| AU (2) | AU2010271582B2 (enExample) |
| BR (1) | BR112012000953A8 (enExample) |
| CA (1) | CA2768204A1 (enExample) |
| DK (1) | DK2454284T3 (enExample) |
| EA (1) | EA031447B1 (enExample) |
| ES (1) | ES2673323T3 (enExample) |
| HK (1) | HK1222418A1 (enExample) |
| HU (1) | HUE038277T2 (enExample) |
| IL (3) | IL217497A (enExample) |
| MX (1) | MX350234B (enExample) |
| NZ (2) | NZ598063A (enExample) |
| PL (1) | PL2454284T3 (enExample) |
| SG (2) | SG177653A1 (enExample) |
| SI (1) | SI2454284T1 (enExample) |
| TR (1) | TR201809128T4 (enExample) |
| TW (2) | TW201610153A (enExample) |
| WO (1) | WO2011008092A2 (enExample) |
| ZA (2) | ZA201200363B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122021001906B1 (pt) | 2005-12-09 | 2022-03-29 | Kling Biotherapeutics B.V. | Método para aumentar a estabilidade de uma célula produtora de anticorpo, método para produzir uma célula produtora de anticorpo que é estável durante pelo menos uma semana, método para produzir linhagem de células b, e método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse |
| WO2007067032A1 (en) | 2005-12-09 | 2007-06-14 | Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| KR20160005143A (ko) | 2009-05-13 | 2016-01-13 | 젠자임 코포레이션 | 항-인간 ｃｄ52 면역글루불린 |
| CA2768204A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Gram-positive bacteria specific binding compounds |
| ES2666584T3 (es) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics B.V. | Medios y métodos para producir anticuerpos de alta afinidad |
| PT2646466T (pt) | 2010-12-02 | 2017-06-07 | Aimm Therapeutics Bv | Meios e métodos para produzir anticorpos de alta afinidade |
| CN102559733A (zh) * | 2012-03-13 | 2012-07-11 | 黑龙江省科学院微生物研究所 | 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法 |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CA2890427C (en) | 2012-11-06 | 2022-05-31 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
| US9809645B2 (en) | 2013-03-12 | 2017-11-07 | Zenyaku Kogyo Kabushikikaisha | Anti-Staphylococcus antibody, method for manufacturing same, and usage of same |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| US9884126B2 (en) * | 2013-05-31 | 2018-02-06 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| MX369022B (es) * | 2013-05-31 | 2019-10-25 | Genentech Inc | Anticuerpos anti-ácido teicoico de la pared celular y conjugados. |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| ES2729057T3 (es) | 2013-12-17 | 2019-10-30 | Aimm Therapeutics Bv | Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos |
| WO2015115892A1 (en) | 2014-01-31 | 2015-08-06 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
| WO2016090038A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
| MX2017007231A (es) * | 2014-12-03 | 2017-11-08 | Genentech Inc | Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. |
| WO2016200926A1 (en) * | 2015-06-09 | 2016-12-15 | Techulon Inc. | Peptide nucleic acid molecules for treatment of gram positive bacterial infection |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| US11280788B2 (en) | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
| KR102301987B1 (ko) * | 2019-11-14 | 2021-09-13 | 연세대학교 산학협력단 | 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트 |
| WO2023129822A2 (en) * | 2021-12-28 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified bacterial peptidoglycan compositions and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2192175A1 (en) | 1994-06-07 | 1995-12-21 | Ambrose Cheung | Surface protein of staphylococcus aureus |
| US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| AU4714196A (en) * | 1995-01-30 | 1996-08-21 | Peter Truog | Antitumor and anticholesterol preparations containing a lipoteichoic acid from steptococcus |
| SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6680195B1 (en) | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| CA2341177A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US6635473B1 (en) | 1998-08-31 | 2003-10-21 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
| US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| WO2000012131A1 (en) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US20030165527A1 (en) | 1998-12-22 | 2003-09-04 | Bengt Guss | Novel fibronectin-binding protein |
| US20040038327A1 (en) | 1999-08-31 | 2004-02-26 | Foster Timothy J. | Antibodies to polypeptides from coagulase-negative staphylococci |
| BR0207068A (pt) | 2001-01-26 | 2004-12-21 | Inhibitex Inc | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus |
| GB0127983D0 (en) * | 2001-11-22 | 2002-01-16 | Neutec Pharma Plc | Treatment of micro-organism infection |
| US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2004025416A2 (en) | 2002-09-13 | 2004-03-25 | The Texas A & M University System | Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| US20040151737A1 (en) | 2003-02-05 | 2004-08-05 | University Of Tennessee | Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| EP1631581A4 (en) * | 2003-05-29 | 2006-10-18 | Inhibitex Inc | SDR PROTEINS FROM STAPHYLOCOCCUS CAPITIS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF INFECTIONS |
| ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| KR20070104590A (ko) * | 2005-01-10 | 2007-10-26 | 나비 바이오파마슈티컬즈 | 스타필로코쿠스 아우레우스 감염을 치료하는 방법 |
| US8475798B2 (en) | 2005-06-16 | 2013-07-02 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| AU2007221321B2 (en) | 2006-02-22 | 2012-06-28 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use |
| EA018030B1 (ru) * | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| CN101302504B (zh) * | 2007-05-11 | 2011-12-21 | 上海高科联合生物技术研发有限公司 | 一种抗体亲和层析纯化溶葡萄球菌酶的方法 |
| MY150531A (en) | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| US20090162379A1 (en) | 2007-10-01 | 2009-06-25 | Magnus Hook | Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor |
| MY188455A (en) | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| HUE031614T2 (en) | 2008-01-31 | 2017-07-28 | The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T | Treatment of microbial infections |
| DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
| WO2010005513A2 (en) | 2008-06-30 | 2010-01-14 | The Texas A&M University System | Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof |
| SI2445522T1 (sl) | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
| CA2768204A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Gram-positive bacteria specific binding compounds |
| AU2010272505B2 (en) | 2009-07-16 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Treatment of infections |
-
2010
- 2010-07-15 CA CA2768204A patent/CA2768204A1/en not_active Abandoned
- 2010-07-15 US US12/837,358 patent/US20110020323A1/en not_active Abandoned
- 2010-07-15 WO PCT/NL2010/050456 patent/WO2011008092A2/en not_active Ceased
- 2010-07-15 PL PL10734844T patent/PL2454284T3/pl unknown
- 2010-07-15 NZ NZ598063A patent/NZ598063A/en not_active IP Right Cessation
- 2010-07-15 DK DK10734844.3T patent/DK2454284T3/en active
- 2010-07-15 SG SG2012002622A patent/SG177653A1/en unknown
- 2010-07-15 SI SI201031701T patent/SI2454284T1/en unknown
- 2010-07-15 NZ NZ616921A patent/NZ616921A/en not_active IP Right Cessation
- 2010-07-15 CN CN201080041138.6A patent/CN102666583B/zh not_active Expired - Fee Related
- 2010-07-15 EP EP10734844.3A patent/EP2454284B1/en not_active Not-in-force
- 2010-07-15 ES ES10734844.3T patent/ES2673323T3/es active Active
- 2010-07-15 JP JP2012520555A patent/JP6192294B2/ja not_active Expired - Fee Related
- 2010-07-15 CN CN201510639968.3A patent/CN105440133A/zh active Pending
- 2010-07-15 MX MX2014012186A patent/MX350234B/es unknown
- 2010-07-15 TW TW104126578A patent/TW201610153A/zh unknown
- 2010-07-15 TW TW099123405A patent/TWI502068B/zh not_active IP Right Cessation
- 2010-07-15 TR TR2018/09128T patent/TR201809128T4/tr unknown
- 2010-07-15 EA EA201390967A patent/EA031447B1/ru not_active IP Right Cessation
- 2010-07-15 AU AU2010271582A patent/AU2010271582B2/en not_active Ceased
- 2010-07-15 BR BR112012000953A patent/BR112012000953A8/pt not_active Application Discontinuation
- 2010-07-15 HU HUE10734844A patent/HUE038277T2/hu unknown
- 2010-07-15 KR KR1020127003839A patent/KR101832201B1/ko not_active Expired - Fee Related
- 2010-07-15 SG SG10201704269RA patent/SG10201704269RA/en unknown
- 2010-07-15 AR ARP100102587A patent/AR077756A1/es unknown
-
2011
- 2011-11-28 US US13/305,659 patent/US8617556B2/en not_active Expired - Fee Related
-
2012
- 2012-01-12 IL IL217497A patent/IL217497A/en not_active IP Right Cessation
- 2012-01-17 ZA ZA2012/00363A patent/ZA201200363B/en unknown
-
2013
- 2013-03-05 US US13/786,215 patent/US9090677B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/786,206 patent/US9399673B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,715 patent/US9266943B2/en not_active Expired - Fee Related
-
2014
- 2014-01-27 ZA ZA2014/00644A patent/ZA201400644B/en unknown
-
2015
- 2015-04-01 IL IL238074A patent/IL238074A/en not_active IP Right Cessation
- 2015-06-02 US US14/728,826 patent/US9458228B2/en not_active Expired - Fee Related
- 2015-10-22 IL IL242207A patent/IL242207A0/en unknown
- 2015-12-28 US US14/981,643 patent/US9688745B2/en not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001939A patent/JP2016135771A/ja active Pending
- 2016-08-24 US US15/246,301 patent/US9927428B2/en not_active Expired - Fee Related
- 2016-09-05 HK HK16110533.5A patent/HK1222418A1/zh unknown
- 2016-10-27 AU AU2016250398A patent/AU2016250398B2/en not_active Ceased
-
2018
- 2018-02-20 US US15/900,589 patent/US20180292391A1/en not_active Abandoned
- 2018-04-04 JP JP2018072444A patent/JP2018134089A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016135771A5 (enExample) | ||
| Gao et al. | Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA) | |
| Assis et al. | New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus | |
| Saylor et al. | Monoclonal antibody-based therapies for microbial diseases | |
| Del Rio et al. | Patients at risk of complications of Staphylococcus aureus bloodstream infection | |
| Ohlsen et al. | Immunotherapeutic strategies to combat staphylococcal infections | |
| JP2021063090A5 (enExample) | ||
| Berry et al. | Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology | |
| Projan et al. | Staphylococcal vaccines and immunotherapy: to dream the impossible dream? | |
| Munita et al. | Enterococcal endocarditis: can we win the war? | |
| JP2017519768A5 (enExample) | ||
| JP2012518624A5 (enExample) | ||
| SG10201811361XA (en) | Treatment of polybacterials infections | |
| SI2454284T1 (en) | Compounds that specifically bind to Gram-positive bacteria | |
| Varshney et al. | Humanized staphylococcal enterotoxin B (SEB)–specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin | |
| BRPI1010948A2 (pt) | Composição compreendendo pelo menos trans- cinamaldeído e a respectiva utilização no tratamento das infecções bacterianas, mais particularmente no tratamento das doenças nosocomiais. | |
| Yagupsky | Antibiotic susceptibility of Kingella kingae isolates from children with skeletal system infections | |
| François et al. | Antibody-based therapy to combat Staphylococcus aureus infections | |
| Rezazadeh et al. | Antibiotic profile of methicillin-resistant Staphylococcus aureus with multiple-drug resistances isolated from nosocomial infections in Vali-Asr Hospital of Arak | |
| Ter Meulen | Monoclonal antibodies in infectious diseases: clinical pipeline in 2011 | |
| JP2024009968A5 (enExample) | ||
| Cunha et al. | Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy | |
| Castanheira et al. | 690. Activity of a novel polymyxin analog, QPX9003, tested against resistant Gram-negative pathogens, including carbapenem-resistant Acinetobacter, Enterobacterales, and Pseudomonas | |
| WO2017137954A3 (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
| Eltwisy et al. | Clinical infections, antibiotic resistance, and pathogenesis of Staphylococcus haemolyticus. Microorganisms 2022, 10, 1130 |